Description
MK-2206 is an allosteric AKT inhibitor developed for treating advanced solid tumors, including metastatic colorectal cancer with specific molecular characteristics. In colorectal cancer, it has been evaluated primarily in patients with KRAS wild-type, PIK3CA-mutated tumors, often in combination with other targeted agents. The drug targets the PI3K/AKT pathway, which is frequently dysregulated in colorectal cancers and contributes to treatment resistance and tumor progression.
Mechanism of Action
MK-2206 works by selectively inhibiting all three isoforms of AKT (AKT1, AKT2, and AKT3) through allosteric binding, preventing AKT activation and downstream signaling. This inhibition blocks the PI3K/AKT/mTOR pathway, leading to reduced cell proliferation, increased apoptosis, and decreased tumor cell survival. The drug is particularly relevant in PIK3CA-mutated colorectal cancers where this pathway is constitutively activated.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.